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1. Introduction 
Nasopharyngeal carcinoma (NPC) is the leading cause of death in Southeast Asian 
populations, especially among Chinese people (338). The specific type of NPC is defined by 
the World Health Organization and classified histologically as either type I (keratinizing 
squamous cell carcinoma), type II (non-keratinizing squamous cell carcinoma), or type III 
(undifferentiated carcinoma) (263). Etiologic factors associated with NPC development are 
classified according to three determinants, including genetic susceptibility, Epstein-Barr 
virus (EBV) infection, and environmental exposure to carcinogens (45, 337). Evidence has 
indicated that EBV infection is implicated in the development of type II and III and is 
observed particularly in Asia (50, 61, 205, 230). EBV infection is generally not detected in 
type I NPC patients, especially in non-endemic areas (221, 342). Potential risk factors 
significantly associated with the initiation and development of type I NPC are cigarette 
smoking and alcohol consumption (35, 225, 295, 301). However, increasing evidence 
indicates that EBV appears to be the predominant risk factor associated with the initiation 
and development of NPC, regardless of histological type (17, 20, 300). In particular, EBV 
infection is an important event in the early stage of the NPC carcinogenesis process before 
tumor formation (101). Clinically, NPC exhibits a high incidence of lymph node spread and 
distant metastasis that is correlated with a poor prognosis, even when employing radiation 
therapy and chemotherapy (43, 260, 326). In the search for new substances with anti-tumoral 
effects, many natural compounds from dietary plants, such as herb and fruit extracts, have 
been shown to inhibit NPC proliferation, invasion, metastasis, and angiogenesis both in vitro 
and in vivo. This review summarizes the molecular mechanisms of EBV infection in NPC 
development as well as the role of natural compounds in the regulation of multiple cellular 
pathways and their clinical importance for the prevention and treatment of NPC. 
2. The molecular mechanisms of EBV infection and the effects on  
NPC growth and metastasis 
Virus binding to the surface of a target cell is a major determinant of cellular tropism and is 
a critical step in viral pathogenesis. This early event initiates the virus replication cycle by 
the attachment of the virus to specific receptor (s) and leads to the release of the viral 
genome into the cytoplasm of the target cell. It is believed that EBV infection is initiated by 
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the interaction of the viral envelope glycoprotein gp350 with the complement receptor 2 
(CR2/CD21) of the primary B cell surface membrane (11, 70, 219). The inefficient infection of 
epithelial cells by EBV is ascribed mainly to the lack of CD21 expression (17). RNA 
transcripts of the CD21 gene have been found in the tonsillar epithelial cells of healthy 
patients by real-time quantitative polymerase chain reaction (PCR), although CD21 protein 
is not detected in these cells (125). A recent study has demonstrated that EBV-binding to the 
surface CD21 protein of CD11b-positive memory B cells (but not CD11b-negative naïve B 
cells) triggers co-capping of virus and integrins on B cells and activation of the adhesion 
molecules, which can induce the conjugation of EBV-loaded B cells and epithelial cells via 
the capped adhesion molecules while providing efficient virus transfer from B cells to infect 
epithelial cells (264). Memory B cells are regarded as professional antigen-presenting cells 
capable of priming T cells, which are responsible for the secretory IgA response and 
protective humoral immunity to virus. The anatomical localization of memory B cells from 
human tonsils preferentially colonize the tonsil epithelium, which is a potential site of viral 
entry, implying that transfer infection of normal epithelial cells may contribute to the EBV-
induced tumorigenesis (191). Immunohistochemical analysis of CD21 in samples derived 
from healthy patients, non-tumoral nasopharyngeal mucosa patients, and NPC patients of 
different histological types with EBV infection has demonstrated a loss of CD21 expression 
in all NPC samples analyzed after EBV infection (18). A study of CD21 expression using a 
sensitive ribonuclease protection assay has demonstrated that a weak transcription signal of 
the CD21 gene can be detected in the transplanted EBV-associated NPC tumors of nude 
mice, thereby suggesting that CD21 is expressed at low levels in EBV-positive NPC cells 
(11). These data suggest that EBV-induced immunophenotypic modulation of CD21 
expression may be associated with NPC malignancy (18). 
During EBV latency, NPC cells express a well-defined set of latent genes, including latent 
membrane proteins (LMP1, LMP2A, and LMP2B) and EBV-determined nuclear antigens 
(EBNA1 and EBNA2) (16, 84, 323). LMP1, an integral membrane protein encoded by the 
BNLF1 gene (115), is the major transforming protein of the virus based on its ability to alter 
the phenotypic properties of epithelial cells and induce the expression of matrix 
metalloproteinase 9 (MMP-9), which is thought to contribute to tumor progression, 
invasiveness, and metastasis of NPC (58, 138, 334). Although low levels of LMP1 protein 
expression have been detected in NPC biopsies (68, 335), the LMP1 gene transcripts detected 
by RT-PCR are present in approximately 95% of nasopharyngeal swab specimens from NPC 
patients (183). Expression of the LMP1 gene was especially observed in early stage NPCs 
and pre-invasive lesions but not in late stage NPCs, therefore suggesting that its expression 
may initiate the development and progression of NPC (230). When the LMP1 gene was 
expressed at high levels, it was toxic to human B-lymphoid cell lines, mouse embryonic 
fibroblast BALB/3T3 cells, a human osteosarcoma 143/EBNA-1 cell line expressing the EBV 
EBNA-1 gene, and the human Larynx carcinoma HEp-2 cell line (93). Stable low-level 
expression of LMP1 is closely associated with the induction of anchorage-dependent growth 
and an invasive phenotype in mouse epithelial cells (294). Results have shown that LMP1-
derived LALLFWL peptides are able to inhibit the proliferation of T cells and the cytotoxic 
function of NK cells (63). Studies have also indicated that EBV-infected NPC cells can use 
the exosome pathway for viral immune escape (134, 140). Moreover, LMP1 was shown to 
colocalize with the major histocompatibility complex (MHC) class II and be presented on the 
exosome (71). LMP1-containing exosomes derived from an EBV-positive lymphoblastoid 
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cell line (LCL) were also capable of reducing T cell proliferation (71). LMP1 exerts 
immunosuppressive activity and can modulate the cytotoxic effects of innate immune cells, 
which are thought to allow cancer cells to evade the immune system (297). Exposure of cells 
to exosomes containing LMP1 prepared from EBV-infected NPC cells leads to the activation 
of the extracellular signal-regulated protein kinase (ERK) and phosphatidylinositol 3-
kinase/protein kinase B (PI3K/Akt) pathways in epithelial, endothelial, and fibroblast cells. 
Moreover, the data presented showed that LMP1 could also induce epidermal growth factor 
receptor (EGFR) expression in EBV-negative epithelial cells and that purified exosomes from 
treated cells contained high levels of EGFR (207). Incorporation of cancer cell-secreted 
EGFR-containing membrane microvesicles by endothelial cells can induce the endothelial 
cell expression of EGFR and lead to the activation of the mitogen-activated protein kinase 
(MAPK) and Akt pathways as well as subsequent increased expression of vascular 
endothelial growth factor (VEGF) (4). These results support the concept that LMP1 plays a 
role in the modulation of the tumor microenvironment and immune evasion of EBV. 
LMP1 also displays pleiotropic effects on the induction of the cell surface adhesion molecule 
CD23 (303), upregulation of the anti-apoptotic genes Bcl-2 and A20 (99, 149), and stimulation 
of interleukin-6 (IL-6) and -8 production (64, 65). LMP1 operates as a constitutively activated 
tumor necrosis factor receptor (TNFR) by functionally mimicking CD40, thereby utilizing 
TNFR-associated factor (TRAF) adaptor proteins to induce signaling pathways in a ligand-
independent manner (241). LMP1-regulated IL-6 production in epithelial cells, which is 
regulated via a nuclear factor-kappa B (NF-κB) pathway involving TRAF, is similar to those 
mediated by the CD40 (65). IL-6 production and cell survival have also been shown to be 
regulated by p38 MAPK activity in LMP1-expressing epithelial cells (59, 64). Recent studies 
have demonstrated that activation of the p38 MAPK signaling pathway can promote LMP1 
expression, suggesting that LMP1 upregulation by p38 MAPK signaling may contribute to 
cell survival during the early stage of EBV infection (126). Moreover, LMP1 expression has a 
significant anti-differentiation effect on human epithelial cells by inducing CD40, CD54, IL-
6, and IL-8 expression (57). The serum levels of IL-6 are usually found to be elevated in NPC 
patients (46). The role that IL-6 plays in the regulation of the growth and invasion of cancer 
cells has been well demonstrated in various cancer cells such as human melanoma (194), 
human ductal breast carcinoma (253), renal cell carcinoma (289), ovarian carcinoma cells 
(243), human oral squamous carcinoma cells (270), head and neck cancer cells (281), human 
chondrosarcoma cells (286), and human pancreatic cancer cells (112). Ectopic expression of 
LMP1 in epithelial cells has been shown to result in increased MMP-9 expression (334). The 
promoter region of MMP-9 contains various cis-acting elements, including potential binding 
sites for NF-B and activator protein-1 (AP-1) (334). NF-B is critically involved in tumor 
progression through transcriptional regulation of invasion related factors, such as MMP-9 
and VEGF (3). NF-B overexpression can protect cancer cells against apoptosis induced by 
death receptors, thereby promoting the proliferation of cancer cells. Furthermore, 
constitutive activation of NF-B has been detected in various tumor cells (224). The 
involvement of the MAPK pathways in NF-B activation has been demonstrated to play an 
important role in tumorigenesis (60). Furthermore, p38 MAPK activity has been reported to 
be associated with anti-apoptosis (220), cell proliferation (103), and cancer invasion (271). 
Collectively, the regulation of IL-6 and MMP-9 production via the LMP1-TRAF-p38-MAPK-
NF-κB pathway may have implications for the tumorigenesis and metastasis of NPC. 
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Dissociation or dissemination of cells from primary cancer to distant organs has been 
characterized by the loss of function or expression of epithelial cell adhesion molecules (148, 
162). E-cadherin is a homophilic adhesion molecule expressed predominantly in epithelial 
tissues, which acts as an invasion suppressor and was found to be downregulated in most 
carcinomas (48). Reduced expression of E-cadherin has been observed in the advanced 
stages of NPC, therefore suggesting its association with cancer metastasis and poor 
prognosis (347). Significantly decreased expression levels of E-cadherin regulated by LMP1 
have been shown to be associated with a higher invasive capability in human epithelial cells 
(67). LMP1 induces the downregulation of E-cadherin gene expression in NPC cell lines, 
which was shown by activation of DNA methyltransferases (292). The recent generation of 
transgenic mice has demonstrated that LMP1 overexpression antagonizes Wingless 
(WNT)/ǃ-catenin signaling through inhibition of the Wilms' tumor gene on the X 
chromosome (WTX) and subsequent promotion of epithelial dysplasia of the nasopharynx 
and oropharynx but not tumorigenesis; downregulation of E-cadherin expression was also 
observed in these mice (240). The study has indicated that a reduction in WTX expression 
caused by LMP1 is associated with epithelial dysplasia via regulation of the WNT/ǃ-catenin 
pathway and E-cadherin expression. 
LMP1 also has effects on inhibition of p53-mediated apoptosis in stable epithelial cells 
expressing the A20 gene (78). Another study has indicated that LMP1 can activate MAPK 
kinases to modulate p53 phosphorylation (167). The p53 gene mutation rate was 
significantly lower in NPC than in other cancers (192, 238, 282). Dominant-negative 
mutations in the DNA-binding domain of the p53 gene are rarely detected in NPC (107). An 
immunohistochemical study has shown significant p53 overexpression in approximately 
82% of primary nasopharyngeal biopsy specimens (2). These results indicate that inhibition 
of p53-mediated apoptosis by LMP1 was probably responsible for p53 overexpression and 
the lack of p53 gene mutations in EBV-positive NPC. 
The LMP2 transcription unit generates two alternatively spliced mRNAs that encode two 
functionally distinct proteins, LMP2A and LMP2B, which differ at their amino terminus 
(336). Only LMP2A has a 119-amino-acid amino-terminal cytoplasmic domain (79). This 
domain contains eight tyrosine residues with two of the tyrosines forming an 
immunoreceptor tyrosine-based activation motif (24, 193, 248). Immunohistochemical 
analysis of paraffin-embedded NPC biopsy samples with the LMP2A monoclonal antibody 
has shown that LMP2A mainly localizes to the tumor cell membrane and is expressed in 
invasive tumor front cells (142). Amino-terminal tyrosine phosphorylation of LMP2A has 
been shown to be necessary for association with Lyn and Syk protein-tyrosine kinases (210). 
In addition, tyrosine phosphorylation of LMP2A in epithelial cells can be triggered by cell 
adhesion to extracellular matrix proteins via the C-terminal Src kinase (257). LMP2A mRNA 
has been detected in all NPC specimens (21), whereas protein expression could be detected 
in only approximately 46% of these specimens (102). Stable expression of LMP2A in 
squamous epithelial cells was shown to promote cell spreading and migration in the 
extracellular matrix that required tyrosine kinase activity (5). Similarly, using primary 
epithelial cells from tonsil tissue that overexpress LMP2A, an increase in cell invasion and 
extracellular matrix receptor integrin-ǂ-6 (ITGǂ6) has been demonstrated, therefore 
suggesting that LMP2 expression may contribute to the invasive process of NPC cells (233). 
Functional studies have indicated that LMP2 can induce the activation of PI3K/Akt, Syk 
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tyrosine kinase, NF-B, signal transducer and activators of transcription (STAT), and -
catenin pathways, thereby resulting in the inhibition of cell differentiation and the induction 
of cell migration in epithelial cells (196, 212, 256, 279, 284). A recent report has demonstrated 
that the ectopic expression of LMP2A in NPC cells induces epithelial-mesenchymal 
transition and increases the self-renewal capacity of cancer stem-like cells, which supports 
the concept that LMP2A functions as a potential inducer of tumor initiation and cellular 
invasiveness in NPC cells (142). 
EBNA1 is a DNA-binding nuclear phosphoprotein that consists of two major functional 
domains, a carboxy-terminal DNA-binding domain and an amino-terminal chromosome 
tethering domain (159, 305). Both domains are separated by a glycine-alanine repeat 
sequence (GAr) that has been identified as a cis-acting inhibitor of MHC-class I-restricted 
antigen presentation (161). It has been recently shown that the GAr suppresses the 
presentation of MHC-class I-restricted antigen through the entire mRNA direct targeting of 
the mRNA translation initiation process (7). These results suggest that EBNA1 interferes 
with virus-encoded protein presentation by the MHC-class I-restricted pathway. 
Furthermore, EBNA1 expression is able to induce growth inhibition by inducing G2/M 
phase arrest in human squamous epithelial cell lines (but not epithelial cell lines of 
glandular origin) (128). These results further indicate that the induction of the cytotoxicity 
effects in human squamous epithelial cells by EBNA1 is associated with EBNA1 degradation 
and processing. This leads to the endogenous degradation of EBNA1 in human squamous 
epithelial cells resulting from a specific cytotoxic T lymphocyte response (128), which 
suggests the possibility of the efficient EBV infection in malignant squamous epithelial cells 
but not in normal epithelial cells. 
The dimerization and DNA-binding domains of EBNA1 have previously been shown to be 
located at the carboxy-terminal domain, amino acids 459 to 487 (36). The DNA-binding 
domain is essential for EBNA1 binding to the origin of plasmid replication (oriP), which is 
required for the replication and maintenance of the episomal EBV genome (237). The 
phosphorylation of EBNA1 is crucial for its transcriptional activity and the stability of EBV 
plasmids in virus-infected cells (62). The formation of the oriP-EBNA1 complex is also 
required for transactivation of the EBV C promoter (Cp), which is involved in the 
rearrangement of chromatin structure induced by EBNA1 (339). Moreover, recruitment of 
the histone H2B deubiquitylating complex to the oriP can be regulated by EBNA1 (254). 
EBNA1 has also been reported to upregulate LMP1 promoter activity (81). The effect of 
EBNA1 in promoting tumorigenesis has been found to increase genomic instability and 
DNA damage by inducing production of reactive oxygen species (ROS) (89). Stable complex 
formation between EBNA1 and the nucleosome assembly proteins, NAP1 and TAF-I, can 
affect cellular DNA replication (309). The EBNA1 portion of the EBNA1-binding protein 2 
complex was shown to promote its interaction with mitotic chromosomes (218). A recent 
study has demonstrated that high-level expression of the EBNA1 protein in NPC cells 
interferes with mitotic segregation (275). 
EBNA1 enhances the activity of the AP-1 transcription factor by binding to the promoter 
regions of c-Jun and activating transcription factor 2 (222). Elevated expression of the AP-1 
targets IL-8, VEGF, and hypoxia-inducible factor-1alpha, has been observed in EBNA1-
expressing NPC cells (222). EBNA1 also induces EBV-encoded RNA (EBER) expression 
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through the induction of EBER-associated cellular transcription factors, ATF-2 and c-Myc, in 
an EBV-infected human adenocarcinoma cell line derived from nasopharynx (226). EBNA1 
expression also influences the expression of genes involved in the dysregulation of 
oncogenic pathways in epithelial 293 cell lines (25) and decreases the expression levels and 
nuclear localization of phosphate-NF-B in NPC cell lines (296). Survivin is a member of the 
family of inhibitors of apoptosis protein (IAP). It is expressed in a number of human cancer 
cells but not in normal adult tissue (6). The anti-apoptotic function of survivin involves its 
ability to block the activity of caspase-3 and caspase-7 (269, 285). Dysregulation of survivin 
expression in NPC cells affects cell viability and induces apoptosis (266, 333). More recent 
studies have demonstrated that EBNA1 forms a complex with SP1 or SP1-like protein at the 
cis-element of the survivin promoter and thereby regulates survivin expression. Results 
have further demonstrated an increase in resistance to apoptosis through upregulation of 
survivin expression by EBNA1 (197). Thus, EBNA1 may regulate multiple cellular signaling 
pathways to control cell proliferation and survival, thereby promoting the development of 
NPC. 
EBNA2 is a nuclear phosphoprotein lacking sequence-specific DNA-binding activity. It was 
found to associate with the chromatin and nuclear matrix (32) and has been identified 
previously as a transcriptional regulator of the expression of cellular and EBV genes 
including AML-2 (RUNX3), CD21, CD23, c-MYC, EBI-1, Hes-1, LMP1, and LMP2A (19, 44, 51, 
80, 85, 130, 152, 255, 278, 303, 304). Their mechanism of regulation is suggested by the 
binding of EBNA2 with cellular transcription factors RBPJ, CBF-2/AUF1 or Spi-1/PU.1 to 
specific response elements of each promoter (137). Recent work has demonstrated that 
human endogenous retrovirus K nuclear protein NP9 can bind to EBNA2 and negatively 
regulate the EBNA2-mediated activation of the EBV viral C- and LMP2A promoters (88). 
The carboxy-terminal acidic activation domain of EBNA2 is required for direct interaction 
with the CSL family of DNA-binding protein (CBF1) and participates in EBNA2-mediated 
gene transcription (306). EBNA2 has been shown to be able to functionally replace the 
intracellular region of Notch in the regulation of gene expression of B cells by targeting 
CBF1 and localizing the coactivators p300, PCAF, and CBP to the promoter (109, 122, 250, 
280, 306, 321). In normal cells, CBF-1 is bound by Notch to regulate the expression of cellular 
genes involved in cell proliferation (14, 187). Lee et al. have demonstrated that like Notch, 
EBNA2 can block orphan nuclear receptor Nur77-mediated apoptosis through interaction 
between its amino acids 123–147 conserved domain and Nur77 (158). Although Notch 
signaling functions have been linked to a variety of cellular processes such as adhesion, 
differentiation, cell proliferation, apoptosis, epithelial to mesenchymal transition, migration, 
and angiogenesis, Notch can also function as an oncogene or a tumor suppressor in cancer 
development (14). The biological effect of Notch signaling depends on the type and fate of 
the cell (244). An immunocytochemical study of NPC biopsies using antibodies against the 
activated form of Notch1 and Hes-1 have demonstrated that Notch signaling is activated in 
human primary NPC cells (345). High expression levels of both Notch and Notch ligand 
(Jagged1) were detected in human head and neck and breast cancer samples, and patients 
harboring these tumors showed poor prognosis (174, 246). Recent studies have indicated 
that activation of Notch signaling contributes to the survival and proliferation of several 
types of cancer entities, such as human non-small cell lung cancer (40), human tongue 
carcinoma (343), human leukemia cells (164), human gastric cancer (332), and human colon 
adenocarcinoma (247). These findings suggest that EBNA2 mimics the effects of Notch, 
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thereby upregulating Notch signaling activity to maintain cell proliferation and survival of 
NPC. 
3. The inhibitory mechanisms of natural compounds against NPC survival 
and metastasis signaling 
The prognosis of NPC is based on the size of the tumor and the spread of the cancer to the 
lymph nodes or to other organs. Traditionally, this type of cancer is treated either with 
surgery, radiotherapy, chemotherapy, immunotherapy, or other methods. The main 
treatment of NPC is radiotherapy, usually given in combination with chemotherapy drugs 
(315). However, NPC exhibits a high incidence of lymph node spread and distant metastasis 
that is correlated with a poor prognosis, even during the use of radiation therapy and 
chemotherapy (43, 260, 326). The currently available chemotherapy agents for cancer 
treatment are usually toxic to normal cells, often resulting in adverse side effects such as 
temporary hair loss, nausea and vomiting. The use of chemopreventative agents is now 
regarded as a promising strategy against cancer development (10). Cancer development and 
progression is a complex process that involves the dysregulation of multiple signaling 
pathways and molecular changes. These events may contribute to tumor growth, invasion, 
metastasis, and immune evasion (27). In the search for new substances with anti-tumoral 
effects, many natural, dietary, or synthetic substances have been shown to inhibit 
carcinogenesis in vitro and in vivo through the targeting of specific proteins or modulating 
signal transduction pathways (133). 
Aloe-emodin (AE; 1,8-dihydroxy-3-(hydroxymethyl)-anthraquinone), which is isolated from 
the rhizomes of Rheum palmatum, has been shown to inhibit cell growth and induce 
apoptosis in vitro in several cancer cell lines, such as human cervical carcinoma HeLa (91), 
rat C6 glioma carcinoma (209), human hepatoma HepG2 (147, 180), human neuroblastoma 
SJ-N-KP and SK-N-BE(2c) (232), human lung squamous carcinoma CH27 (155), and human 
lung non-small cell carcinoma H460 cell lines (331). Animal studies using severe combined 
immune deficiency (SCID) mice have shown that AE selectively inhibited the growth of 
human neuroectodermal tumors but not normal fibroblasts and hematopoietic progenitor 
cells (231). The results of a recent in vitro study have shown that high concentrations (up to 
100 M) of AE exhibit low cytotoxicity in normal human fibroblasts WI-38, Detroit 551, and 
MRC-5 cells (178), which are consistent with evidence provided by other reports in other 
normal cells including the proximal tubule-derived opossum kidney OK cell line, the 
human keratinocyte HACAT cell line, the human airway epithelial BEAS-2B cell line (195), 
and rat primary astrocytes (209). AE also inhibited the proliferation of both human umbilical 
vein endothelial and bovine aortic endothelial cells (28). These results suggest that the effect 
of AE is highly specific for cancer cells and endothelial cells, thereby supporting the concept 
that AE could be a potent cancer chemotherapeutic and anti-angiogenic agent. Apoptosis is 
a physiological mechanism involved in the elimination of malignant or cancer cells without 
eliciting damage to normal cells or surrounding tissues. Thus, the induction of apoptosis 
exclusively in target cells is an attractive approach for anticancer therapy (133). It is now 
recognized that the mitochondria play a crucial role in the regulation of cell death, which 
seems to be the main target for apoptosis induction in response to a variety of stress stimuli, 
such as growth factor withdrawal and chemopreventative components (133). Bcl-2 and Bcl-
XL have been well characterized as important regulators of apoptosis in response to a wide 
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range of stimuli, including chemopreventative components (1, 272). In addition, the ability 
of Bcl-2 and Bcl-XL to suppress the mitochondrial-mediated pathway of apoptosis is well 
known (86, 87, 310). Overexpression of either Bcl-2 or Bcl-XL in tumor cells has been shown 
to be associated with poor prognosis in many human cancers (52) and contributes to the 
development of resistance to chemotherapy and radiation treatment (127, 261). Although 
EBV LMP1 can block apoptosis in B cells by upregulating Bcl-2 expression (99), knockdown 
of Bcl-XL by siRNA has been shown to induce apoptosis in NPC cells (166), thereby 
suggesting that Bcl-XL is an important effector of resistance to apoptosis in NPC cells. A 
recent in vitro NPC cell study has shown that increasing levels of cyclin B1 bound to cyclin-
dependent kinase 2 contributes to 60 M AE-induced G2/M phase cell cycle arrest (178). AE 
(60 M)-induced apoptosis of NPC-TW076 and NPC-TW039 cells was mediated by elevated 
Bax and decreased Bcl-XL expression, which was confirmed by ectopic expression of Bcl-XL, 
although it was not observed in Bcl-2 or small interfering RNA (siRNA)-mediated 
attenuation of Bax suppressing AE-induced apoptotic cell death (178). The reduction of 
mitochondrial membrane potential and the increase in cellular Ca2+ content, ROS 
production, and apoptosis induced by AE were attenuated by treatment with either 
cyclosporin A or the caspase-8 inhibitor Z-IETD-FMK. Further analysis has shown that 
suppression of caspase-8 with the specific inhibitor Z-IETD-FMK inhibited AE-induced 
activation of Bax, the cleavage of Bid, the translocation of tBid to the mitochondria, and the 
release of cytochrome c, apoptosis-inducing factor and endonuclease G from the 
mitochondria, and subsequent apoptosis. These results indicate that caspase-8-mediated 
activation of the mitochondrial death pathway plays a critical role in 60 M AE-induced 
apoptosis of NPC cells (178). A more recent investigation has revealed that 40 M AE 
significantly inhibits NPC cell growth through cell cycle arrest at the S-G2/M phase, which 
is associated with increased levels of cyclin B1 bound to Cdk1 but not the apoptotic process 
(179). Gene silencing of MMP-2 mediated by siRNA inhibits NPC cell invasion, thereby 
demonstrating the involvement of MMP-2 in the NPC invasion process (179). Using siRNA 
against p38 MAPK, the p38 MAPK inhibitor SB203580, NF-B inhibitors N-p-tosyl-L-
phenylalanine chloromethyl ketone and pyrrolidine dithiocarbamate, transient ectopic 
expression of wild type NF-B, a MMP-2 promoter activity assay, and an NF-B-dependent 
reporter assay it has been further demonstrated that 40 M AE inhibits the invasion of NPC 
cells by reducing the expression of MMP-2, likely through the inhibition of the p38 MAPK-
NF-B pathway, and that NF-κB activity is involved in regulating the expression of MMP-2 
and VEGF through the p38 MAPK-dependent pathway (179). The reason that NPC cells are 
more sensitive to 60 M than 40 M AE for the induction of apoptosis remains unclear. AE 
was found to induce DNA single-strand breaks and nuclear condensation through the 
generation of ROS, leading to apoptosis in the human lung non-small cell carcinoma H460 
cell line (156). Previous studies have also reported that the release of the nuclear protein 
nucleophosmin from the nucleus to the cytosol is associated with AE-induced cell apoptosis 
(157). These observations led to the speculation that nuclear DNA might be a target of AE 
during AE-induced apoptotic cell death. The results from another group have shown that 
AE displayed an affinity for nuclear DNA; disrupted chromatin structure and DNA 
template function were detected in susceptible cell lines upon treatment with a high dose of 
AE (214). The participation of ROS in cancer cell apoptosis stimulated by chemotherapeutic 
agents through the induction of DNA damage has been investigated for several decades 
(154). Oxidative damage to DNA is a result of the interaction of DNA with ROS. AE contains 
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a quinone structure that was predicted to have the ability to induce ROS production, which 
may play a role in the induction of cancer cell apoptosis (156). Consistent with the data 
presented by Lee et al. (156), an increase in intracellular ROS levels was observed when 
apoptosis was induced in NPC cells using 60 M AE (178). However, apoptosis, DNA 
damage, and increases in ROS levels were not detected in the same cells treated with 40 M 
AE, therefore suggesting that different concentrations of AE could differentially modulate 
the expression of cellular genes that are involved in cell growth, apoptosis, and cell invasion 
in different types of cancer cells (179). 
Berberine (2,3-Methylenedioxy-9,10-dimethoxyprotoberberine chloride), is an isoquinoline 
plant alkaloid isolated from the roots, rhizomes, and stem bark of Hydrastis Canadensis, 
Coptis chinensis, Berberis aquifolium, Berberis vulgaris, Berberis aristata, and Berberis thunbergii 
(143). It is traditionally used in China to treat gastrointestinal diseases such as dysentery and 
diarrhea. Clinical studies conducted in 1985 and 1987 have shown that berberine is 
considered to be a non-toxic alkaloid and is useful for the treatment of bacterial diarrhea 
(136, 242). Berberine also has anti-fungal (76), anti-human immunodeficiency virus (HIV) 
infection (53), and anti-protozoan properties (131). Berberine-induced apoptosis of cancer 
cells likely involves the enhanced activities of the mitochondria-dependent signaling events 
or Fas/FasL signaling as implied by the loss of mitochondrial membrane potential (Δψm) 
and the release of cytochrome c in human colonic carcinoma SW620 (118), promonocytic 
U937 (121), leukemia HL-60 (169), and oral cancer HSC-3 cell lines (170); the decrease of Bcl-
XL and Bcl-2 expression in human epidermoid carcinoma A431 cell lines (204); and the 
generation of ROS and activation of FasL in human colonic carcinoma SW620 cell lines (111). 
Other signaling pathways have also been shown to be required for berberine-induced 
apoptosis, including the JNK/p38 MAPK (111), p53-dependent ATF3 (235), ER stress (172), 
and NF-B pathways (227). In addition to apoptosis induction, berberine has also shown 
potent anti-angiogenic effects on the inhibition of tumor-induced angiogenesis and MMP-1, 
-2, and -9 expression (313). Berberine inhibits the invasion of human lung cancer A549 cells 
in vitro by decreasing the production of the urokinase-plasminogen activator and MMP-2 
(234). The inhibition of cell invasion by berberine through downregulation of MMP-2 and -9 
expression was also observed in human breast cancer MDA-MB-231 (139), gastric cancer 
SNU-5 (173), glioma U-87 (184), and tongue squamous carcinoma SSC-4 cell lines (106). 
Moreover, oral administration of berberine in mice significantly inhibited the spontaneous 
mediastinal lymph node metastasis of Lewis lung carcinoma into the lung parenchyma 
(211). In NPC cells, berberine inhibits the intracranial invasion of tumors in nude mice 
injected with NPC 5-8F cells through the induction of NM23-H1 expression (190). Other 
investigations have also found that berberine exerts a potent in vitro anti-invasive effect on 
the NPC 5-8F cell line through the reduction of filopodia formation (287). Significant 
inhibition of tumor metastasis to the lymph nodes and a decrease in Ezrin phosphorylation 
at threonine 567 (Thr567) in metastatic samples were observed in nude mice injected via 
intravenous (tail vein) injection with NPC 5-8F cell lines and treated with berberine. The 
authors further demonstrated that berberine-induced reduction in filopodia formation was 
associated with decreased Rho kinase-mediated Ezrin phosphorylation at Thr567 (287). 
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is a polyphenol 
isolated from the rhizomes of Curcuma longa, which has demonstrated low toxicity in 
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humans (299). It has been shown to inhibit cell growth and induce apoptosis in vitro in 
several cancer cell lines, such as breast cancer; human basal cell carcinoma BCC-1/KMC 
(123); biliary cancer KKU100, KKU-M156 and KKU-M213 (239); colon cancer HT-29 and 
HCT116 (124, 129, 314); esophageal adenocarcinoma OE33 (95); hepatoma HepG2 (26, 124, 
308); myeloid leukemia U937 and HL60 (252); liposarcoma SW872 (307); lung 
adenocarcinoma A549 (38, 39, 340, 341); lung squamous carcinoma H520 (258); 
medulloblastoma MED (8); neuroblastoma Lan-5, SK-N-SH, and Kelly (77); esophageal 
cancer OE21 and OE33 (223); prostate carcinoma PC3 (105); salivary adenoid cystic 
carcinoma SACC-83 (283); and small cell lung cancer NCI-H446 and PC-9 cell lines (249, 322, 
328). In vitro cell culture studies have shown that curcumin can also suppress the migration 
and invasion of human cancer cell lines, such as breast carcinoma MDA-MB-231 and MDA-
MB-468 (217, 277); colon cancer HCT116 (213, 311); gastric cancer BGC823 (23); glioblastoma 
A-172, MZ-18, MZ-54, MZ-256, and MZ-304 (259); hepatocellular carcinoma SK-Hep-1 (175); 
lung adenocarcinoma A549 and CL1-5 (33, 182); medulloblastoma MED (8, 34); and prostate 
cancer PC-3 cell lines (100). Animal studies using SCID mice have shown that curcumin 
selectively inhibits the growth of human breast, colon, gastric, liver, ovarian, and brain 
cancers but not normal tissues (144). Curcumin also induces apoptosis and cell growth 
arrest in cancer cells by modulating the expression of cell cycle regulatory factors, inhibiting 
the transcriptional regulation of NF-B, and activating the activities of caspases (144). In 
addition, curcumin blocks angiogenesis and metastasis by modulating the signaling 
pathways involved in the expression of growth factors and cell adhesion molecules (144). 
Although the anti-cancer mechanisms of curcumin that are involved in the modulation of 
signal transducer and activator pathways to interrupt the process of carcinogenesis are 
diverse (144, 317), it exhibits potential as an anti-cancer chemotherapeutic agent for the 
treatment of many human cancers. Curcumin’s inhibitory effect on NPC cell migration has 
been demonstrated to increase the expression of E-cadherin (320). Conversely, curcumin 
exerts an apoptotic effect on NPC cells through the decrease in the relative ratio of Bcl-2 to 
Bax, dysfunction of the mitochondria, cytochrome c release, and the activation of caspase-9 
and caspase-3, therefore indicating that the mitochondrial death pathway is involved in the 
curcumin-induced apoptosis of NPC cells (145). 
Epigallocatechin gallate (EGCG), also known as epigallocatechin 3-gallate, is a polyphenol 
isolated from green tea leaves (329). EGCG has been reported to possess several biochemical 
and pharmacological properties, which include anti-HIV and HCV infection activity (49, 94, 
318, 325), reduction of Sjögren's syndrome in murine models (83, 110), prevention of 
Alzheimer’s and Parkinson’s diseases (203), anti-obesity effects on mice and humans (41, 
319), anti-oxidant activity (75, 104, 293, 348), and anti-neoplastic activity (135, 262). The 
cancer-preventive effects of EGCG have been proposed to suppress the transformative, 
hyperproliferative, and inflammatory processes that are involved in carcinogenesis (288). 
The anti-oxidant activity of EGCG is thought to play an important role in the induction of 
apoptotic signaling pathways in cancer cells (104, 151), such as human hepatoma Hepa1c1c7 
(151), cervical cancer HeLa (274), chondrosarcoma (330), lung cancer H1299 (165), and 
glioblastoma T98G and U87MG cell lines (56). EGCG displays anti-oxidant activity due to 
the presence of phenolic groups in the molecule that are sensitive to oxidation (151, 215). 
However, the molecular targets of EGCG in the inhibition of cancer growth, metastasis, and 
angiogenesis are diverse. EGCG also affects various signaling pathways (273). Yan et al. 
have showed that EGCG inhibits the growth of NPC CNE-LMP1 cell lines by suppressing 
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LMP-1-induced NF-κB activity via the inhibition of inhibitory protein IkappaBǂ 
phosphorylation (327). LMP-1-promoted activator protein-1 (AP-1) transcriptional activity, 
the nuclear translocation of JNK, the phosphorylation of c-Jun, promoter activity and 
phosphorylation of EGFR, and cyclin D expression in NPC CNE-LMP1 cell lines were also 
suppressed by EGCG (327, 346), thereby suggesting that EGCG suppresses LMP-1-mediated 
NPC cell growth through the inhibition of AP-1 and NF-κB signaling pathways. 
Osajin (5-hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6-(3-methylbut-2-enyl) pyrano[2,3-
h]chromen-4-one;5-Hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6-(3-methyl-2-butenyl)-
4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one) is a prenylated isoflavone originally isolated from 
the fruit of Maclura pomifera (302). The biological activity of osajin is thought to have anti-
oxidant properties that can attenuate the myocardial dysfunction provoked by ischemia 
reperfusion in rats (72). It has been shown to inhibit the growth of six types of human cancer 
cell lines in vitro, including renal carcinoma ACHN, lung adenocarcinoma NCI-H23, 
prostate cancer PC-3, breast cancer MDA-MB-231, melanoma LOX-IMVI, and colon 
carcinoma HCT-15 cell lines (276). Osajin has demonstrated low toxicity in human 
hepatocytes compared with human cancer cell lines (276). However, the mechanism of 
growth inhibition in human cancer cells by osajin is not clear. A recent study has shown that 
the activation of the death receptor Fas/FasL, mitochondrial death, and endoplasmic 
reticulum (ER) stress signaling pathways are involved in the apoptosis of NPC cells induced 
by osajin (114). 
Resveratrol (3,4,5-trihydroxy-trans-stilbene), a polyphenol phytoalexin, is widely present in 
foods such as grapes, berries, peanuts, and other plant sources. It has been shown to possess 
diverse biochemical and physiological functions, including anti-aging (9), anti-platelet 
aggregation (201, 312), anti-inflammatory (268), cardioprotection (15, 116, 119), and 
estrogenic properties (160). Experimental results from animal models have revealed that the 
anti-inflammatory properties of resveratrol control the development of arthritis (66), 
pancreatitis (198, 199), and colitis (153). Although resveratrol is a poor ROS scavenger in 
vitro, it behaves as a potent anti-oxidant due to its ability to increase the synthesis of nitric 
oxide in vivo (22, 54, 96, 324). During the last decade, resveratrol has been shown to have 
strong anti-carcinogenic activity in a wide range of human cancer cell lines, such as 
anaplastic large-cell lymphoma SR-786 (141), breast cancer MCF-7 and MDA-MB231 (267), 
chronic myeloid leukemia K562 (132), colon cancer HT-29 (298), diffuse large B cell 
lymphoma DLBCL (117), glioblastoma A172 and T98G (171), glioma U87 (69), hepatocellular 
carcinoma Huh-7 (168), leukemia HL-60 (163), leukemic monocyte lymphoma U937 (90), 
lung adenocarcinoma ASTC-a-1 (344), medullary thyroid cancer (291), melanoma YUZAZ6 
and M14 (290), neuroblastoma B65 (236), non-small cell lung cancer A549 (188, 189), and 
prostate cancer LNCaP cell lines (37). Resveratrol also been shown to suppress the growth of 
cancer in vivo such as colon (55, 316), hepatocellular (13), lung (200), mammary (31), and 
skin cancer (82). In vitro and in vivo studies have led to several clinical trials to evaluate 
resveratrol’s potential for cancer chemoprevention and chemotherapy, including the 
prevention and treatment of colon cancer (12, 228, 229). The anti-cancer activity of 
resveratrol has been attributed to the induction of apoptotic cell death via its anti-
proliferation and anti-invasion properties (216, 228). Its mechanism of action and molecular 
targets are diverse (216, 228). In human NPC TWP4 cells, treatment with resveratrol induced 
apoptosis and was associated with the induction of multiple apoptotic pathways, including 
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death receptor, mitochondria, and ER stress pathways (113). Chow et al. have suggested that 
ΔNp63 is a molecular target of resveratrol-induced apoptosis in NPC-TW076 and NPC-
TW039 cell lines (47). 
Rhein (4, 5-dihydroxyanthraquinone-2-carboxylic acid), a major constituent in the rhizome 
of rhubarb, shows anti-oxidant and free radical scavenging effects similar to AE, which has 
been shown to play an important role in the inhibition of carcinogenesis (202). In addition to 
the inhibitory effects on the process of hepatic fibrosis in rats (92), synthesis of aggrecan and 
tissue inhibitor of metalloproteinases-1 in cultured human chondrocytes (251), activation of 
the MEK/ERK pathway induced by IL-1 in chondrocytes cultured in hypoxia (206), and 
fungal infection of plants (349), rhein also protects the dysfunction of human umbilical 
endothelium ECV-304 cell lines induced by transforming growth factor 1 through the 
inhibition of plasminogen activator inhibitor-1 (350). In vivo experimental results have 
shown that rhein has the ability to suppress the growth of tumor cells in rat liver (208). The 
anti-angiogenic property of rhein has been characterized in a zebrafish model (97, 98). 
Interestingly, rhein lysinate showed a synergistic increase in the anti-tumor activity of Taxol 
in mice (185, 186). It has also been shown to influence cell growth and apoptosis in several 
human cancer cell lines such as cervical cancer Ca Ski (120), colon adenocarcinoma CaCo-2 
(245), glioma U-373MG (74), hepatocellular carcinoma BEL-7402 (265), hepatoblastoma 
HepG2 (146), lung cancer A549 (108), promyelocytic leukemia HL-60 (181), and human 
tongue SSC-4 cancer cell lines (42, 150). Moreover, rhein can inhibit the uptake and 
glycolysis of glucose and protein synthesis in cancer cells (29, 30, 73). Although it has been 
reported that increased expression of p53, p21, and CD96 may be responsible for the 
apoptosis of human hepatoblastoma HepG2 cell lines induced by rhein in a similar manner 
to AE (146), the molecular mechanisms by which rhein influences cell growth and apoptosis 
of cancer cells differ from AE. In NPC-TW076 and -TW039 cells, rhein induces apoptotic cell 
death via the ER stress and Ca2+-dependent mitochondrial death pathways. The induction of 
ER stress by rhein correlated with the augmented expression of glucose-regulated protein 
78, PKR-like ER kinase, activating transcription factor 6 and CCAAT/enhancer-binding 
protein homologous protein as well as the cleavage of procaspase-12 (176). In addition, NPC 
cells exposed to rhein have demonstrated a dramatic increase in mitochondrial dysfunction, 
including the loss of Δψm and the release of cytochrome c and apoptosis-inducing factor 
(176). Lin et al. have further demonstrated that rhein inhibits the invasion of NPC cells by 
suppressing the expression of MMP-9 and VEGF via the NF-B signaling pathway (177). 
4. Conclusion 
Although numerous studies have attempted to define the initiation and development of 
NPC, the exact mechanism remains controversial. The understanding of the signaling 
pathways and regulatory mechanisms leading to NPC carcinogenesis will provide sufficient 
information for the identification of potent chemopreventive agents against NPC. Based on 
the studies discussed here, there is strong evidence that the anti-NPC activities of AE, 
berberine, curcumin, osajin, resveratrol, and rhein involve the inhibition of cell growth and 
metastasis as well as the induction of apoptosis through modulation of multiple signaling 
pathways and molecular factors. Further studies should attempt to analyze other active 
components or chemotherapeutic agents and integrate with in vivo studies and clinical trials 
to evaluate the applicability of these natural compounds in NPC prevention and treatment. 
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